Emerging evidence for the role of neurotransmitters in the modulation of T cell responses to cognate ligands

Central Nervous System Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 65-83

  Pacheco, Rodrigo ^a,b   Riquelme, Erick ^c   Kalergis, Alexis Mikes ^c,d,e  

^a Fundacion Ciencia para la Vida   (Chile)

^b UNIVERSIDAD SAN SEBASTIÁN   (Chile)

^c Pontificia Universidad Católica de Chile   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Adaptive immune response; Antigen presenting cells; Neurotransmitter receptors; Neurotransmitters; Regulatory T cells; T cell mediated immunity

Indexed keywords

ACETYLCHOLINE; CYTOKINE; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; SEROTONIN; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CELL FUNCTION; CELL INTERACTION; CELLULAR IMMUNITY; DENDRITIC CELL; DISEASE COURSE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 77951110216     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152410790780154     Document Type: Review

References (175)

1. Wong, P.; Pamer, E.G. CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol., 2003, 21, 29-70.
2. Meunier, M.C.; Delisle, J.S.; Bergeron, J.; Rineau, V.; Baron, C.; Perreault, C. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat. Med., 2005, 11(11), 1222-1229. (Pubitemid 43093670)
3. Badovinac, V.P.; Harty, J.T. Programming, demarcating, and manipulating CD8+ T-cell memory. Immunol. Rev., 2006, 211, 67-80.
4. Farber, D.L. Differential TCR signaling and the generation of memory T cells. J. Immunol., 1998, 160(2), 535-539.
5. Parker, D.C. T cell-dependent B cell activation. Annu. Rev. Immunol., 1993, 11, 331-360.
6. Denkers, E.Y.; Gazzinelli, R.T. Regulation and function of T-cellmediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev., 1998, 11(4), 569-588.
7. Nouri-Shirazi, M.; Banchereau, J.; Fay, J.; Palucka, K. Dendritic cell based tumor vaccines. Immunol. Lett., 2000, 74(1), 5-10.
8. Schoenborn, J.R.; Wilson, C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol., 2007, 96, 41-101. (Pubitemid 350018717)
9. Ye, Z.; Tang, C.; Xu, S.; Zhang, B.; Zhang, X.; Moyana, T.; Yang, J.; Xiang, J. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Cell Mol. Immunol., 2007, 4(4), 277-285.
10. Prezzi, C.; Casciaro, M.A.; Francavilla, V.; Schiaffella, E.; Finocchi, L.; Chircu, L.V.; Bruno, G.; Sette, A.; Abrignani, S.; Barnaba, V. Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur. J. Immunol., 2001, 31(3), 894-906. (Pubitemid 32237126)
11. Cerwenka, A.; Morgan, T.M.; Harmsen, A.G.; Dutton, R.W. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J. Exp. Med., 1999, 189(2), 423-434.
12. Accapezzato, D.; Francavilla, V.; Paroli, M.; Casciaro, M.; Chircu, L.V.; Cividini, A.; Abrignani, S.; Mondelli, M.U.; Barnaba, V. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J. Clin. Invest., 2004, 113(7), 963-972. (Pubitemid 38544117)
13. Anichini, A.; Mortarini, R.; Romagnoli, L.; Baldassari, P.; Cabras, A.; Carlo-Stella, C.; Gianni, A.M.; Di Nicola, M. Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines. Blood, 2006, 107(2), 602-609. (Pubitemid 43076384)
14. Ito, N.; Nakamura, H.; Tanaka, Y.; Ohgi, S. Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer, 1999, 85(11), 2359-2367. (Pubitemid 29244844)
15. Ochi, H.; Wu, X.M.; Osoegawa, M.; Horiuchi, I.; Minohara, M.; Murai, H.; Ohyagi, Y.; Furuya, H.; Kira, J. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyper Ig Eaemic myelitis. J. Neuroimmunol., 2001, 119(2), 297-305. (Pubitemid 32918338)
16. Inaoki, M.; Sato, S.; Shirasaki, F.; Mukaida, N.; Takehara, K. The frequency of type 2 CD8+ T cells is increased in peripheral blood from patients with psoriasis vulgaris. J. Clin. Immunol., 2003, 23(4), 269-278. (Pubitemid 36870669)
17. Schoenberger, S.P.; Toes, R.E.; van der Voort, E.I.; Offringa, R.; Melief, C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 1998, 393(6684), 480-483. (Pubitemid 28292196)
18. Ridge, J.P.; Di Rosa, F.; Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature, 1998, 393(6684), 474-478. (Pubitemid 28292194)
19. Bennett, S.R.; Carbone, F.R.; Karamalis, F.; Flavell, R.A.; Miller, J.F.; Heath, W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature, 1998, 393(6684), 478-480. (Pubitemid 28292195)
20. Smith, K.M.; Pottage, L.; Thomas, E.R.; Leishman, A.J.; Doig, T.N.; Xu, D.; Liew, F.Y.; Garside, P. Th1 and Th2 CD4+ T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo. J. Immunol., 2000, 165(6), 3136-3144.
21. McGeachy, M.J.; Cua, D.J. Th17 cell differentiation: the long and winding road. Immunity, 2008, 28(4), 445-453. (Pubitemid 351467042)
22. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature, 1998, 392(6673), 245-252.
23. Lanzavecchia, A.; Sallusto, F. Regulation of T cell immunity by dendritic cells. Cell, 2001, 106(3), 263-266. (Pubitemid 32772609)
24. Watford, W.T.; Moriguchi, M.; Morinobu, A.; O'Shea, J.J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev., 2003, 14(5), 361-368. (Pubitemid 37099449)
25. Del Prete, G. The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int. Rev. Immunol., 1998, 16(3-4), 427-455. (Pubitemid 28102263)
26. Friedl, P.; den Boer, A.T.; Gunzer, M. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat. Rev. Immunol., 2005, 5(7), 532-545. (Pubitemid 40961331)
27. Davis, D.M.; Dustin, M.L. What is the importance of the immunological synapse? Trends Immunol., 2004, 25(6), 323-327.
28. Iruretagoyena, M.I.; Tobar, J.A.; Gonzalez, P.A.; Sepulveda, S.E.; Figueroa, C.A.; Burgos, R.A.; Hancke, J.L.; Kalergis, A.M. Andro-grapholide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J. Pharmacol. Exp. Ther., 2005, 312(1), 366-372.
29. Iruretagoyena, M.I.; Sepulveda, S.E.; Lezana, J.P.; Hermoso, M.; Bronfman, M.; Gutierrez, M.A.; Jacobelli, S.H.; Kalergis, A.M. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther., 2006, 318(1), 59-67. (Pubitemid 43920742)
30. Iruretagoyena, M.I.; Wiesendanger, M.; Kalergis, A.M. The dendritic cell-T cell synapse as a determinant of autoimmune pathogenesis. Curr. Pharm. Des., 2006, 12(2), 131-147.
31. Iruretagoyena, M.I.; Riedel, C.A.; Leiva, E.D.; Gutierrez, M.A.; Jacobelli, S.H.; Kalergis, A.M. Activating and inhibitory Fcgamma receptors can differentially modulate T cell-mediated autoimmunity. Eur. J. Immunol., 2008, 38(8), 2241-2250.
32. Herrada, A.A.; Contreras, F.J.; Tobar, J.A.; Pacheco, R.; Kalergis, A.M. Immune complex-induced enhancement of bacterial antigen presentation requires Fcgamma receptor III expression on dendritic cells. Proc. Natl. Acad. Sci. USA, 2007, 104(33), 13402-13407.
33. Kalergis, A.M.; Iruretagoyena, M.I.; Barrientos, M.J.; Gonzalez, P.A.; Herrada, A.A.; Leiva, E.D.; Gutierrez, M.A.; Riedel, C.A.; Bueno, S.M.; Jacobelli, S.H. Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus. Immunology, 2009, 128(Suppl. 1), e306-e314.
34. Pacheco, R.; Martinez-Navio, J.M.; Lejeune, M.; Climent, N.; Oliva, H.; Gatell, J.M.; Gallart, T.; Mallol, J.; Lluis, C.; Franco, R. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc. Natl. Acad. Sci. USA, 2005, 102(27), 9583-9588. (Pubitemid 40981724)
35. Tobar, J.A.; Gonzalez, P.A.; Kalergis, A.M. Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc gamma receptors on dendritic cells. J. Immunol., 2004, 173(6), 4058-4065.
36. Kalergis, A.M. Modulation of T cell immunity by TCR/pMHC dwell time and activating/inhibitory receptor pairs on the antigen-presenting cell. Curr. Pharm. Des., 2003, 9(3), 233-244.
37. Carreno, L.J.; Bueno, S.M.; Bull, P.; Nathenson, S.G.; Kalergis, A.M. The half-life of the T-cell receptor/peptide-major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge. Immunology, 2007, 121(2), 227-237.
38. Coombs, D.; Kalergis, A.M.; Nathenson, S.G.; Wofsy, C.; Goldstein, B. Activated TCRs remain marked for internalization after dissociation from pMHC. Nat. Immunol., 2002, 3(10), 926-931. (Pubitemid 35154005)
39. Gonzalez, P.A.; Carreno, L.J.; Figueroa, C.A.; Kalergis, A.M. Modulation of immunological synapse by membrane-bound and soluble ligands. Cytokine Growth Factor Rev., 2007, 18(1-2), 19-31.
40. Kalergis, A.M.; Boucheron, N.; Doucey, M.A.; Palmieri, E.; Goyarts, E.C.; Vegh, Z.; Luescher, I.F.; Nathenson, S.G. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol., 2001, 2(3), 229-234.
41. Carreno, L.J.; Gonzalez, P.A.; Kalergis, A.M. Modulation of T cell function by TCR/pMHC binding kinetics. Immunobiology, 2006, 211(1-2), 47-64. (Pubitemid 43150108)
42. Zheng, Y.; Manzotti, C.N.; Liu, M.; Burke, F.; Mead, K.I.; Sansom, D.M. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J. Immunol., 2004, 172(5), 2778-2784.
43. Jansson, A.; Barnes, E.; Klenerman, P.; Harlen, M.; Sorensen, P.; Davis, S.J.; Nilsson, P. A theoretical framework for quantitative analysis of the molecular basis of costimulation. J. Immunol., 2005, 175(3), 1575-1585. (Pubitemid 41023059)
44. Vasu, C.; Wang, A.; Gorla, S.R.; Kaithamana, S.; Prabhakar, B.S.; Holterman, M.J. CD80 and CD86 C domains play an important role in receptor binding and co-stimulatory properties. Int. Immunol., 2003, 15(2), 167-175.
45. Pentcheva-Hoang, T.; Egen, J.G.; Wojnoonski, K.; Allison, J.P. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity, 2004, 21(3), 401-413.
46. Perez, N.; Karumuthil-Melethil, S.; Li, R.; Prabhakar, B.S.; Holterman, M.J.; Vasu, C. Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+) -adaptive regulatory T cell generation. J. Immunol., 2008, 180(10), 6566-6576.
47. Diehl, S.; Rincon, M. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol., 2002, 39(9), 531-536. (Pubitemid 35341492)
48. Gaudreau, S.; Guindi, C.; Menard, M.; Besin, G.; Dupuis, G.; Amrani, A. Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J. Immunol., 2007, 179(6), 3638-3647.
49. Mahnke, K.; Johnson, T.S.; Ring, S.; Enk, A.H. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J. Dermatol. Sci., 2007, 46(3), 159-167.
50. Franco, R.; Pacheco, R.; Lluis, C.; Ahern, G.P.; O'Connell, P.J. The emergence of neurotransmitters as immune modulators. Trends Immunol., 2007, 28(9), 400-407.
51. Pacheco, R.; Ciruela, F.; Casado, V.; Mallol, J.; Gallart, T.; Lluis, C.; Franco, R. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J. Biol. Chem., 2004, 279(32), 33352-33358. (Pubitemid 39062983)
52. Pacheco, R.; Gallart, T.; Lluis, C.; Franco, R. Role of glutamate on T-cell mediated immunity. J. Neuroimmunol., 2007, 185(1-2), 9-19. (Pubitemid 46497434)
53. Besser, M.J.; Ganor, Y.; Levite, M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J. Neuroimmunol., 2005, 169(1-2), 161-171. (Pubitemid 41528789)
54. Watanabe, Y.; Nakayama, T.; Nagakubo, D.; Hieshima, K.; Jin, Z.; Katou, F.; Hashimoto, K.; Yoshie, O. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J. Immunol., 2006, 176(2), 848-856. (Pubitemid 43099681)
55. Saha, B.; Mondal, A.C.; Majumder, J.; Basu, S.; Dasgupta, P.S. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor- mediated mechanism. Neuroimmunomodulation, 2001, 9(1), 23-33.
56. Sarkar, C.; Das, S.; Chakroborty, D.; Chowdhury, U.R.; Basu, B.; Dasgupta, P.S.; Basu, S. Cutting Edge: Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J. Immunol., 2006, 177(11), 7525-7529.
57. Leon-Ponte, M.; Ahern, G.P.; O'Connell, P.J. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood, 2007, 109(8), 3139-3146.
58. Kawashima, K.; Fujii, T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci., 2003, 74(6), 675-696. (Pubitemid 37494897)
59. Elenkov, I.J.; Wilder, R.L.; Chrousos, G.P.; Vizi, E.S. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev., 2000, 52(4), 595-638.
60. Tian, J.; Lu, Y.; Zhang, H.; Chau, C.H.; Dang, H.N.; Kaufman, D.L. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J. Immunol., 2004, 173(8), 5298-5304.
61. Nakano, K.; Higashi, T.; Hashimoto, K.; Takagi, R.; Tanaka, Y.; Matsushita, S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun., 2008, 373(2), 286-291.
62. Katoh, N.; Soga, F.; Nara, T.; Tamagawa-Mineoka, R.; Nin, M.; Kotani, H.; Masuda, K.; Kishimoto, S. Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clin. Exp. Immunol., 2006, 146(2), 354-361. (Pubitemid 44581352)
63. Kawashima, K.; Yoshikawa, K.; Fujii, Y.X.; Moriwaki, Y.; Misawa, H. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci., 2007, 80(24-25), 2314-2319.
64. Maestroni, G.J.; Mazzola, P. Langerhans cells beta 2- adrenoceptors: role in migration, cytokine production, Th priming and contact hypersensitivity. J. Neuroimmunol., 2003, 144(1-2), 91-99. (Pubitemid 37329933)
65. Wrona, D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J. Neuroimmunol., 2006, 172(1-2), 38-58. (Pubitemid 43277489)
66. O'Connell, P.J.; Wang, X.; Leon-Ponte, M.; Griffiths, C.; Pingle, S.C.; Ahern, G.P. A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood, 2006, 107(3), 1010-1017.
67. Nishibori, M.; Takahashi, H.K.; Mori, S. The regulation of ICAM- 1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses. J. Pharmacol. Sci., 2003, 92(1), 7-12. (Pubitemid 36705662)
68. Beck, G.; Brinkkoetter, P.; Hanusch, C.; Schulte, J.; van Ackern, K.; van der Woude, F.J.; Yard, B.A. Clinical review: immuno-modulatory effects of dopamine in general inflammation. Crit. Care, 2004, 8(6), 485-491.
69. Pacheco, R.; Oliva, H.; Martinez-Navio, J.M.; Climent, N.; Ciruela, F.; Gatell, J.M.; Gallart, T.; Mallol, J.; Lluis, C.; Franco, R. Glutamate released by dendritic cells as a novel modulator of T cell activation. J. Immunol., 2006, 177(10), 6695-6704. (Pubitemid 44715033)
70. Saha, B.; Mondal, A.C.; Basu, S.; Dasgupta, P.S. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int. Immunopharmacol., 2001, 1(7), 1363-1374.
71. Mignini, F.; Streccioni, V.; Amenta, F. Autonomic innervation of immune organs and neuroimmune modulation. Auton. Autacoid Pharmacol., 2003, 23(1), 1-25. (Pubitemid 36917752)
72. Owens, T.; Tran, E.; Hassan-Zahraee, M.; Krakowski, M. Immune cell entry to the CNS - a focus for immunoregulation of EAE. Res. Immunol., 1998, 149(9), 781-789; discussion 844-786, 855-1760
73. Vajkoczy, P.; Laschinger, M.; Engelhardt, B. Alpha4-integrin- VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J. Clin. Invest., 2001, 108(4), 557-565.
74. Kivisakk, P.; Trebst, C.; Liu, Z.; Tucky, B.H.; Sorensen, T.L.; Rudick, R.A.; Mack, M.; Ransohoff, R.M. T-cells in the cerebro-spinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin. Exp. Immunol., 2002, 129(3), 510-518.
75. Biernacki, K.; Prat, A.; Blain, M.; Antel, J.P. Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells. J. Neuropathol. Exp. Neurol., 2001, 60(12), 1127-1136.
76. Kebir, H.; Kreymborg, K.; Ifergan, I.; Dodelet-Devillers, A.; Cayrol, R.; Bernard, M.; Giuliani, F.; Arbour, N.; Becher, B.; Prat, A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med., 2007, 13(10), 1173-1175.
77. Cosentino, M.; Bombelli, R.; Ferrari, M.; Marino, F.; Rasini, E.; Maestroni, G.J.; Conti, A.; Boveri, M.; Lecchini, S.; Frigo, G. HPLC-ED measurement of endogenous catecholamines in human immune cells and hematopoietic cell lines. Life Sci., 2000, 68(3), 283-295.
78. Strange, P.G. New insights into dopamine receptors in the central nervous system. Neurochem. Int., 1993, 22(3), 223-236.
79. Sibley, D.R.; Monsma, F.J., Jr.; Shen, Y. Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol., 1993, 35, 391-415.
80. Neve, K.A.; Seamans, J.K.; Trantham-Davidson, H. Dopamine receptor signaling. J. Recept. Signal Transduct. Res., 2004, 24(3), 165-205.
81. Sidhu, A. Coupling of D1 and D5 dopamine receptors to multiple G proteins: Implications for understanding the diversity in receptor- G protein coupling. Mol. Neurobiol., 1998, 16(2), 125-134.
82. Ramstad, C.; Sundvold, V.; Johansen, H.K.; Lea, T. cAMP-dependent protein kinase (PKA) inhibits T cell activation by phosphorylating ser-43 of raf-1 in the MAPK/ERK pathway. Cell Signal, 2000, 12(8), 557-563.
83. Harada, Y.; Miyatake, S.; Arai, K.; Watanabe, S. Cyclic AMP inhibits the activity of c-Jun N-terminal kinase (JNKp46) but not JNKp55 and ERK2 in human helper T lymphocytes. Biochem. Biophys. Res. Commun., 1999, 266(1), 129-134.
84. Vang, T.; Torgersen, K.M.; Sundvold, V.; Saxena, M.; Levy, F.O.; Skalhegg, B.S.; Hansson, V.; Mustelin, T.; Tasken, K. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J. Exp. Med., 2001, 193(4), 497-507.
85. Jimenez, J.L.; Punzon, C.; Navarro, J.; Munoz-Fernandez, M.A.; Fresno, M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther., 2001, 299(2), 753-759.
86. Hershfield, M.S. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur. J. Immunol., 2005, 35(1), 25-30.
87. Aandahl, E.M.; Moretto, W.J.; Haslett, P.A.; Vang, T.; Bryn, T.; Tasken, K.; Nixon, D.F. Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J. Immunol., 2002, 169(2), 802-808.
88. Ilani, T.; Strous, R.D.; Fuchs, S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J., 2004, 18(13), 1600-1602.
89. Yusuf, I.; Fruman, D.A. Regulation of quiescence in lymphocytes. Trends Immunol., 2003, 24(7), 380-386.
90. Giorelli, M.; Livrea, P.; Trojano, M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J. Interferon Cytokine Res., 2005, 25(7), 395-406.
91. Kipnis, J.; Cardon, M.; Avidan, H.; Lewitus, G.M.; Mordechay, S.; Rolls, A.; Shani, Y.; Schwartz, M. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J. Neurosci., 2004, 24(27), 6133-6143.
92. Nakanishi, S. Molecular diversity of glutamate receptors and implications for brain function. Science, 1992, 258(5082), 597-603.
93. Pin, J.P.; Duvoisin, R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 1995, 34(1), 1-26.
94. Pin, J.P.; Acher, F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr. Drug Targets CNS Neurol. Disord., 2002, 1(3), 297-317.
95. Hinoi, E.; Takarada, T.; Ueshima, T.; Tsuchihashi, Y.; Yoneda, Y. Glutamate signaling in peripheral tissues. Eur. J. Biochem., 2004, 271(1), 1-13.
96. Divino Filho, J.C.; Hazel, S.J.; Furst, P.; Bergstrom, J.; Hall, K. Glutamate concentration in plasma, erythrocyte and muscle in relation to plasma levels of insulin-like growth factor (IGF)-I, IGF binding protein-1 and insulin in patients on haemodialysis. J. Endocrinol., 1998, 156(3), 519-527.
97. Graham, T.E.; Sgro, V.; Friars, D.; Gibala, M.J. Glutamate ingestion: the plasma and muscle free amino acid pools of resting humans. Am. J. Physiol. Endocrinol. Metab., 2000, 278(1), E83-89.
98. Tsai, P.J.; Huang, P.C. Circadian variations in plasma and erythrocyte concentrations of glutamate, glutamine, and alanine in men on a diet without and with added monosodium glutamate. Metabolism, 1999, 48(11), 1455-1460.
99. Ganor, Y.; Besser, M.; Ben-Zakay, N.; Unger, T.; Levite, M. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J. Immunol., 2003, 170(8), 4362-4372.
100. Miglio, G.; Dianzani, C.; Fallarini, S.; Fantozzi, R.; Lombardi, G. Stimulation of N-methyl-D-aspartate receptors modulates Jurkat T cell growth and adhesion to fibronectin. Biochem. Biophys. Res. Commun., 2007, 361(2), 404-409.
101. Mashkina, A.P.; Tyulina, O.V.; Solovyova, T.I.; Kovalenko, E.I.; Kanevski, L.M.; Johnson, P.; Boldyrev, A.A. The excitotoxic effect of NMDA on human lymphocyte immune function. Neurochem. Int., 2007, 51(6-7), 356-360.
102. Lombardi, G.; Dianzani, C.; Miglio, G.; Canonico, P.L.; Fantozzi, R. Characterization of ionotropic glutamate receptors in human lymphocytes. Br. J. Pharmacol., 2001, 133(6), 936-944.
103. Poulopoulou, C.; Markakis, I.; Davaki, P.; Nikolaou, C.; Poulopoulos, A.; Raptis, E.; Vassilopoulos, D. Modulation of voltage-gated potassium channels in human T lymphocytes by extracellular glutamate. Mol. Pharmacol., 2005, 67(3), 856-867.
104. Sarchielli, P.; Di Filippo, M.; Candeliere, A.; Chiasserini, D.; Mattioni, A.; Tenaglia, S.; Bonucci, M.; Calabresi, P. Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J. Neuroimmunol., 2007, 188(1-2), 146-158.
105. Bonacho, M.G.; Cardinali, D.P.; Castrillon, P.; Cutrera, R.A.; Esquifino, A.I. Aging-induced changes in 24-h rhythms of mitogenic responses, lymphocyte subset populations and neurotransmitter and amino acid content in rat submaxillary lymph nodes during Freund's adjuvant arthritis. Exp. Gerontol., 2001, 36(2), 267-282.
106. Chiocchetti, A.; Miglio, G.; Mesturini, R.; Varsaldi, F.; Mocellin, M.; Orilieri, E.; Dianzani, C.; Fantozzi, R.; Dianzani, U.; Lombardi, G. Group I mGlu receptor stimulation inhibits activation- induced cell death of human T lymphocytes. Br. J. Pharmacol., 2006, 148(6), 760-768.
107. Ganor, Y.; Teichberg, V.I.; Levite, M. TCR activation eliminates glutamate receptor GluR3 from the cell surface of normal human T cells, via an autocrine/paracrine granzyme B-mediated proteolytic cleavage. J. Immunol., 2007, 178(2), 683-692.
108. Morizane, S.; Suzuki, D.; Tsuji, K.; Oono, T.; Iwatsuki, K. The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles. Br. J. Dermatol., 2005, 153(5), 981-986.
109. Grossman, W.J.; Verbsky, J.W.; Tollefsen, B.L.; Kemper, C.; Atkinson, J.P.; Ley, T.J. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood, 2004, 104(9), 2840-2848.
110. Boldyrev, A.A.; Kazey, V.I.; Leinsoo, T.A.; Mashkina, A.P.; Tyulina, O.V.; Johnson, P.; Tuneva, J.O.; Chittur, S.; Carpenter, D.O. Rodent lymphocytes express functionally active glutamate receptors. Biochem. Biophys. Res. Commun., 2004, 324(1), 133-139.
111. Rezzani, R.; Corsetti, G.; Rodella, L.; Angoscini, P.; Lonati, C.; Bianchi, R. Cyclosporine-A treatment inhibits the expression of metabotropic glutamate receptors in rat thymus. Acta Histochem., 2003, 105(1), 81-87.
112. Langmead, C.J.; Watson, J.; Reavill, C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther., 2008, 117(2), 232-243.
113. Kalamida, D.; Poulas, K.; Avramopoulou, V.; Fostieri, E.; Lagoumintzis, G.; Lazaridis, K.; Sideri, A.; Zouridakis, M.; Tzartos, S.J. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J., 2007, 274(15), 3799-3845.
114. Kawashima, K.; Fujii, T.; Watanabe, Y.; Misawa, H. Acetylcholine synthesis and muscarinic receptor subtype mRNA expression in T-lymphocytes. Life Sci., 1998, 62(17-18), 1701-1705.
115. Rinner, I.; Schauenstein, K. Detection of choline-acetyltransferase activity in lymphocytes. J. Neurosci. Res., 1993, 35(2), 188-191.
116. Kawashima, K.; Fujii, T. The lymphocytic cholinergic system and its biological function. Life Sci., 2003, 72(18-19), 2101-2109.
117. Sato, K.Z.; Fujii, T.; Watanabe, Y.; Yamada, S.; Ando, T.; Kazuko, F.; Kawashima, K. Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci. Lett., 1999, 266(1), 17-20.
118. Hellstrom-Lindahl, E.; Nordberg, A. Muscarinic receptor subtypes in subpopulations of human blood mononuclear cells as analyzed by RT-PCR technique. J. Neuroimmunol., 1996, 68(1-2), 139-144.
119. Fujii, T.; Kawashima, K. Ca2+ oscillation and c-fos gene expression induced via muscarinic acetylcholine receptor in human T- and B-cell lines. Naunyn Schmiedebergs Arch Pharmacol., 2000, 362(1), 14-21.
120. Fujino, H.; Kitamura, Y.; Yada, T.; Uehara, T.; Nomura, Y. Stimulatory roles of muscarinic acetylcholine receptors on T cell antigen receptor/CD3 complex-mediated interleukin-2 production in human peripheral blood lymphocytes. Mol. Pharmacol., 1997, 51(6), 1007-1014.
121. Fujii, T.; Kawashima, K. Calcium signaling and c-Fos gene expression via M3 muscarinic acetylcholine receptors in human T- and B-cells. Jpn. J. Pharmacol., 2000, 84(2), 124-132.
122. Fujii, T.; Watanabe, Y.; Inoue, T.; Kawashima, K. Upregulation of mRNA encoding the M5 muscarinic acetylcholine receptor in human T- and B-lymphocytes during immunological responses. Neurochem. Res., 2003, 28(3-4), 423-429.
123. Zimring, J.C.; Kapp, L.M.; Yamada, M.; Wess, J.; Kapp, J.A. Regulation of CD8+ cytolytic T lymphocyte differentiation by a cholinergic pathway. J. Neuroimmunol., 2005, 164(1-2), 66-75.
124. Fujii, Y.X.; Tashiro, A.; Arimoto, K.; Fujigaya, H.; Moriwaki, Y.; Misawa, H.; Fujii, T.; Matsui, M.; Kasahara, T.; Kawashima, K. Diminished antigen-specific IgG1 and interleukin-6 production and acetylcholinesterase expression in combined M1 and M5 muscarinic acetylcholine receptor knockout mice. J. Neuroimmunol., 2007, 188(1-2), 80-85.
125. Ueda, A.; Chandswang, N.; Ovary, Z. The action of interleukin-4 on antigen-specific IgG1 and IgE production by interaction of in vivo primed B cells and carrier-specific cloned Th2 cells. Cell. Immunol., 1990, 128(1), 31-40.
126. van Ommen, R.; Vredendaal, A.E.; Savelkoul, H.F. Suppression of polyclonal and antigen-specific murine IgG1 but not IgE responses by neutralizing interleukin-6 in vivo. Eur. J. Immunol., 1994, 24(6), 1396-1403.
127. Fujii, T.; Takada-Takatori, Y.; Kawashima, K. Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J. Pharmacol. Sci., 2008, 106(2), 186-192.
128. Hallquist, N.; Hakki, A.; Wecker, L.; Friedman, H.; Pross, S. Differential effects of nicotine and aging on splenocyte proliferation and the production of Th1- versus Th2-type cytokines. Proc. Soc. Exp. Biol. Med., 2000, 224(3), 141-146.
129. Fujii, Y.X.; Fujigaya, H.; Moriwaki, Y.; Misawa, H.; Kasahara, T.; Grando, S.A.; Kawashima, K. Enhanced serum antigen-specific IgG1 and proinflammatory cytokine production in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. J. Neuroimmunol., 2007, 189(1-2), 69-74.
130. Gao, F.G.; Wan da, F.; Gu, J.R. Ex vivo nicotine stimulation augments the efficacy of therapeutic bone marrow-derived dendritic cell vaccination. Clin. Cancer Res., 2007, 13(12), 3706-3712.
131. Nichols, D.E.; Nichols, C.D. Serotonin receptors. Chem. Rev., 2008, 108(5), 1614-1641.
132. Culafic, D.M.; Mirkovic, D.S.; Vukcevic, M.D.; Rudic, J.S. Plasma and platelet serotonin levels in patients with liver cirrhosis. World J. Gastroenterol., 2007, 13(43), 5750-5753.
133. Brenner, B.; Harney, J.T.; Ahmed, B.A.; Jeffus, B.C.; Unal, R.; Mehta, J.L.; Kilic, F. Plasma serotonin levels and the platelet serotonin transporter. J. Neurochem., 2007, 102(1), 206-215.
134. Tsao, C.W.; Lin, Y.S.; Cheng, J.T.; Lin, C.F.; Wu, H.T.; Wu, S.R.; Tsai, W.H. Interferon-{alpha}-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J. Psychopharmacol., 2008, 22(7), 753-760.
135. Young, M.R.; Kut, J.L.; Coogan, M.P.; Wright, M.A.; Young, M.E.; Matthews, J. Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low-dose exogenous serotonin. Immunology, 1993, 80(3), 395-400.
136. Khan, N.A.; Poisson, J.P. 5-HT3 receptor-channels coupled with Na+ influx in human T cells: role in T cell activation. J. Neuroimmunol., 1999, 99(1), 53-60.
137. Khan, N.A.; Hichami, A. Ionotrophic 5-hydroxytryptamine type 3 receptor activates the protein kinase C-dependent phospholipase D pathway in human T-cells. Biochem. J., 1999, 344(Pt 1), 199-204.
138. Yin, J.; Albert, R.H.; Tretiakova, A.P.; Jameson, B.A. 5-HT(1B) receptors play a prominent role in the proliferation of Tlymphocytes. J. Neuroimmunol., 2006, 181(1-2), 68-81.
139. Aune, T.M.; Golden, H.W.; McGrath, K.M. Inhibitors of serotonin synthesis and antagonists of serotonin 1A receptors inhibit T lymphocyte function in vitro and cell-mediated immunity in vivo. J. Immunol., 1994, 153(2), 489-498.
140. Hellstrand, K.; Hermodsson, S. Enhancement of human natural killer cell cytotoxicity by serotonin: role of non-T/CD16+ NK cells, accessory monocytes, and 5-HT1A receptors. Cell. Immunol., 1990, 127(1), 199-214.
141. Laberge, S.; Cruikshank, W.W.; Beer, D.J.; Center, D.M. Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells in vitro. J. Immunol., 1996, 156(1), 310-315.
142. Idzko, M.; Panther, E.; Stratz, C.; Muller, T.; Bayer, H.; Zissel, G.; Durk, T.; Sorichter, S.; Di Virgilio, F.; Geissler, M.; Fiebich, B.; Herouy, Y.; Elsner, P.; Norgauer, J.; Ferrari, D. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J. Immunol., 2004, 172(10), 6011-6019.
143. Lazarewicz, J.W.; Ziembowicz, A.; Matyja, E.; Stafiej, A.; Zieminska, E. Homocysteine-evoked 45Ca release in the rabbit hippocampus is mediated by both NMDA and group I metabotropic glutamate receptors: in vivo microdialysis study. Neurochem. Res., 2003, 28(2), 259-269.
144. Shi, Q.; Savage, J.E.; Hufeisen, S.J.; Rauser, L.; Grajkowska, E.; Ernsberger, P.; Wroblewski, J.T.; Nadeau, J.H.; Roth, B.L. L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J. Pharmacol. Exp. Ther., 2003, 305(1), 131-142.
145. Gortz, P.; Hoinkes, A.; Fleischer, W.; Otto, F.; Schwahn, B.; Wendel, U.; Siebler, M. Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity. J. Neurol. Sci., 2004, 218(1-2), 109-114.
146. LeBlanc, J.; Ducharme, M.B. Plasma dopamine and noradrenaline variations in response to stress. Physiol. Behav., 2007, 91(2-3), 208-211.
147. Ghosh, M.C.; Mondal, A.C.; Basu, S.; Banerjee, S.; Majumder, J.; Bhattacharya, D.; Dasgupta, P.S. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int. Immunopharmacol., 2003, 3(7), 1019-1026.
148. Lee, M.S.; Cheng, F.C.; Yeh, H.Z.; Liou, T.Y.; Liu, J.H. Determination of plasma serotonin and 5-hydroxyindoleacetic acid in healthy subjects and cancer patients. Clin. Chem., 2000, 46(3), 422-423.
149. Eugen-Olsen, J.; Afzelius, P.; Andresen, L.; Iversen, J.; Kronborg, G.; Aabech, P.; Nielsen, J.O.; Hofmann, B. Serotonin modulates immune function in T cells from HIV-seropositive subjects. Clin. Immunol. Immunopathol., 1997, 84(2), 115-121.
150. Frick, L.R.; Palumbo, M.L.; Zappia, M.P.; Brocco, M.A.; Cremaschi, G.A.; Genaro, A.M. Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. Biochem. Pharmacol., 2008, 75(9), 1817-1826.
151. Zhu, B.Q.; Heeschen, C.; Sievers, R.E.; Karliner, J.S.; Parmley, W.W.; Glantz, S.A.; Cooke, J.P. Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell, 2003, 4(3), 191-196.
152. Dijkstra, C.D.; van der Voort, E.R.; De Groot, C.J.; Huitinga, I.; Uitdehaag, B.M.; Polman, C.H.; Berkenbosch, F. Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology, 1994, 19(2), 135-142.
153. Kim, Y.K.; Myint, A.M.; Lee, B.H.; Han, C.S.; Lee, H.J.; Kim, D.J.; Leonard, B.E. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 28(7), 1129-1134.
154. Avgustin, B.; Wraber, B.; Tavcar, R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat. Med. J., 2005, 46(2), 268-274.
155. Gemignani, F.; Landi, S.; Moreno, V.; Gioia-Patricola, L.; Chabrier, A.; Guino, E.; Navarro, M.; Cambray, M.; Capella, G.; Canzian, F. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev., 2005, 14(7), 1633-1638. (Pubitemid 40995072)
156. Iwasaki, Y.; Ikeda, K.; Kinoshita, M. Plasma amino acid levels in patients with amyotrophic lateral sclerosis. J. Neurol. Sci., 1992, 107(2), 219-222.
157. Basun, H.; Forssell, L.G.; Almkvist, O.; Cowburn, R.F.; Eklof, R.; Winblad, B.; Wetterberg, L. Amino acid concentrations in cerebro-spinal fluid and plasma in Alzheimer's disease and healthy control subjects. J. Neural. Transm. Park. Dis. Dement. Sect., 1990, 2(4), 295-304.
158. Janjua, N.A.; Itano, T.; Kugoh, T.; Hosokawa, K.; Nakano, M.; Matsui, H.; Hatase, O. Familial increase in plasma glutamic acid in epilepsy. Epilepsy Res., 1992, 11(1), 37-44.
159. Castillo, J.; Martinez, F.; Corredera, E.; Aldrey, J.M.; Noya, M. Amino acid transmitters in patients with headache during the acute phase of cerebrovascular ischemic disease. Stroke, 1995, 26(11), 2035-2039.
160. Anthony, M.; Lance, J.W. Plasma serotonin in patients with chronic tension headaches. J. Neurol. Neurosurg. Psychiatry, 1989, 52(2), 182-184.
161. Ferrarese, C.; Aliprandi, A.; Tremolizzo, L.; Stanzani, L.; De Micheli, A.; Dolara, A.; Frattola, L. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology, 2001, 57(4), 671-675.
162. Iwasaki, Y.; Ikeda, K.; Shiojima, T.; Kinoshita, M. Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease. Neurosci. Lett., 1992, 145(2), 175-177.
163. De Cristobal, J.; Madrigal, J.L.; Lizasoain, I.; Lorenzo, P.; Leza, J.C.; Moro, M.A. Aspirin inhibits stress-induced increase in plasma glutamate, brain oxidative damage and ATP fall in rats. Neuroreport, 2002, 13(2), 217-221.
164. Pampliega, O.; Domercq, M.; Villoslada, P.; Sepulcre, J.; Rodriguez- Antiguedad, A.; Matute, C. Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis. J. Neuroimmunol., 2008, 195(1-2), 194-198.
165. Parbtani, A.; Frampton, G.; Yewdall, V.; Kasai, N.; Cameron, J.S. Platelet and plasma serotonin in glomerulonephritis. III: The nephritis of systemic lupus erythematosus. Clin. Nephrol., 1980, 14(4), 164-172.
166. Ollenschlager, G.; Karner, J.; Karner-Hanusch, J.; Jansen, S.; Schindler, J.; Roth, E. Plasma glutamate - a prognostic marker of cancer and of other immunodeficiency syndromes? Scand. J. Clin. Lab. Invest., 1989, 49(8), 773-777.
167. Barbanti, P.; Fabbrini, G.; Ricci, A.; Bruno, G.; Cerbo, R.; Bronzetti, E.; Amenta, F.; Luigi Lenzi, G. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech. Ageing Dev., 2000, 120(1-3), 65-75.
168. Poulopoulou, C.; Davaki, P.; Koliaraki, V.; Kolovou, D.; Markakis, I.; Vassilopoulos, D. Reduced expression of metabotropic glutamate receptor 2mRNA in T cells of ALS patients. Ann. Neurol., 2005, 58(6), 946-949.
169. Barbanti, P.; Bronzetti, E.; Ricci, A.; Cerbo, R.; Fabbrini, G.; Buzzi, M.G.; Amenta, F.; Lenzi, G.L. Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine? Neurosci. Lett., 1996, 207(2), 73-76.
170. Barbanti, P.; Fabbrini, G.; Ricci, A.; Pascali, M.P.; Bronzetti, E.; Amenta, F.; Lenzi, G.L.; Cerbo, R. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia, 2000, 20(1), 15-19.
171. Nagai, Y.; Ueno, S.; Saeki, Y.; Soga, F.; Hirano, M.; Yanagihara, T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology, 1996, 46(3), 791-795.
172. Boneberg, E.M.; von Seydlitz, E.; Propster, K.; Watzl, H.; Rockstroh, B.; Illges, H. D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4+ -T cells. J. Neuroimmunol., 2006, 173(1-2), 180-187.
173. Ilani, T.; Ben-Shachar, D.; Strous, R.D.; Mazor, M.; Sheinkman, A.; Kotler, M.; Fuchs, S. A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. USA, 2001, 98(2), 625-628.
174. Kwak, Y.T.; Koo, M.S.; Choi, C.H.; Sunwoo, I. Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients. BMC Med. Genet., 2001, 2, 3.
175. Perl, O.; Ilani, T.; Strous, R.D.; Lapidus, R.; Fuchs, S. The alpha7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. FASEB J., 2003, 17(13), 1948-1950.